FSD Pharma Inc. | WebDisclosure

Basculer en Français

11046	Companies
242189	Keywords
170558	Articles
130377	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 5 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 6 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 6 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 6 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 6 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 6 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 6 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 6 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 09/22/2026 at 14:00, 1 hour ago

GameSquare and Chartis Announce Strategic Data Partnership to Measure Brand and Creator Impact for User-Generated Content (UGC) Across Gaming
Published on 09/22/2026 at 14:00, 1 hour ago

374Water to Present New Supercritical Water Oxidation Destruction Data at WEFTEC 2026
Published on 09/22/2026 at 14:00, 1 hour ago

NuRAN Wireless to Pilot Starlink LEO Satellite Backhaul for Rural 4G Expansion and Edge AI Enablement
Published on 09/22/2026 at 13:45, 1 hour 15 minutes ago

Galway Metals Announces $14 Million Brokered Private Placement Led by Michael Gentile
Published on 09/22/2026 at 13:30, 1 hour 30 minutes ago

Silver X Increases Measured and Indicated Resources 173% to 10.4 Mt at 213 g/t AgEq (70.8 Moz AgEq) and Inferred Resources 43% to 21.6 Mt at 252 g/t AgEq (180.9 Moz AgEq)

View all ACCESSWIRE

EQS Group

Published on 09/22/2026 at 14:38, 21 minutes ago

Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 09/22/2026 at 14:33, 26 minutes ago

EPH Group AG develops exclusive luxury resort with around 300 beds in Burgenland, Austria
Published on 09/22/2026 at 14:17, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/22/2026 at 14:17, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/22/2026 at 14:16, 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

Les Echos

Published on 09/21/2026 at 18:19, 20 hours 40 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain du 14 au 18 septembre 2026
Published on 09/21/2026 at 18:19, 20 hours 40 minutes ago

Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 20 hours 58 minutes ago

Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 21 hours 14 minutes ago

WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 17:46, 21 hours 14 minutes ago

WEB SA - RESULTATS SEMESTRIELS STATUTAIRES AU 30/06/2026

View all LES ECHOS COMFI WIRE